Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anesthesiology
Pipeline update - CNS 7056
July 10th, 2007
CeNeS Pharmaceuticals plc (AIM: CEN), the Cambridge based biopharmaceutical company today announces new data on its short-acting sedative, CNS 7056. These preclinical data show that CNS 7056 induces deep sedation, has a rapid onset of action and rapid offset of action with predictable effects over a wide range of doses. On the basis of this successful outcome, the compound will be developed for the indications of induction and maintenance of anaesthesia in addition to sedation for day-case procedures. CeNeS also announces that the first full academic paper on CNS 7056 will be published in the July issue of the leading journal 'Anesthesiology'. The paper is one of a small number highlighted...
Source: Drug Law Weekly (2007-07-10)
|
|
Advertisement |
|
|
|
